New smart drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06752681
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 21 times
Summary
This early-phase study tests a new drug called DAY301 in about 254 adults with advanced solid tumors (like ovarian, lung, or breast cancer) that have not responded to standard treatments. DAY301 is designed to deliver a toxin directly to cancer cells by targeting a protein called PTK7. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site: 001-039
RECRUITINGNew York, New York, 10021, United States
-
Site: 001-057
RECRUITINGSan Antonio, Texas, 78229, United States
-
Site: 001-058
RECRUITINGNew Haven, Connecticut, 06510, United States
-
Site: 001-059
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Site: 001-060
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Site: 001-063
RECRUITINGLake Mary, Florida, 32746, United States
-
Site: 001-064
RECRUITINGSarasota, Florida, 34232, United States
-
Site: 001-065
RECRUITINGNashville, Tennessee, 37203, United States
-
Site: 001-069
RECRUITINGHouston, Texas, 77030, United States
-
Site: 001-073
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
Site: 011-005
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Site: 011-013
RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
Conditions
Explore the condition pages connected to this study.